Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
J Am Vet Med Assoc. 2013 Jul 1;243(1):96-101. doi: 10.2460/javma.243.1.96.

Ulnar osteosarcoma in dogs: 30 cases (1992-2008).

Author information

  • 1Department of Surgery, Animal Medical Center, New York, NY 10065, USA. r_sivacolundhu@yahoo.com

Abstract

OBJECTIVE:

To examine the biological behavior of ulnar osteosarcoma and evaluate predictors of survival time in dogs.

DESIGN:

Retrospective case series.

ANIMALS:

30 dogs with primary ulnar osteosarcoma.

PROCEDURES:

Medical records were reviewed. Variables recorded and examined to identify predictors of survival time were signalment, tumor location in the ulna, tumor length, serum alkaline phosphatase activity, surgery type, completeness of excision, tumor stage, tumor grade, histologic subtype, development of metastases, and use of chemotherapy.

RESULTS:

30 cases were identified from 9 institutions. Eleven dogs were treated with partial ulnar ostectomy and 14 with amputation; in 5 dogs, a resection was not performed. Twenty-two dogs received chemotherapy. Median disease-free interval and survival time were 437 and 463 days, respectively. Negative prognostic factors for survival time determined via univariate analyses were histologic subtype and development of lung metastases. Telangiectatic or telangiectatic-mixed subtype (n = 5) was the only negative prognostic factor identified via multivariate analysis (median survival time, 208 days). Dogs with telangiectatic subtype were 6.99 times as likely to die of the disease.

CONCLUSIONS AND CLINICAL RELEVANCE:

The prognosis for ulnar osteosarcoma in this population was no worse and may have been better than the prognosis for dogs with osteosarcoma involving other appendicular sites. Partial ulnar ostectomy was associated with a low complication rate and good to excellent function and did not compromise survival time. Telangiectatic or telangiectatic-mixed histologic subtype was a negative prognostic factor for survival time. The efficacy of chemotherapy requires further evaluation.

PMID:
23786196
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Atypon
    Loading ...
    Write to the Help Desk